Efficacy Analysis of PTCD + TACE Vs PTCD + Apatinib in the Treatment of HCC with Obstructive Jaundice: A Retrospective Study

Overview

Journal Anticancer Agents Med Chem

Publisher Bentham Science Publishers

Specialties Chemistry
Oncology

Date 2024 Jul 22

PMID 39034727

Authors

Haohao Lu

Bin Liang

Xiangwen Xia

Chuansheng Zheng

Affiliations

Soon will be listed here.

Abstract

Purpose: The aim was to evaluate the safety and effectiveness of PTCD combined with TACE in the treatment of hepatocellular carcinoma with obstructive jaundice and to compare the efficacy of TACE in patients with different levels of bilirubin after PTCD.

Methods: The clinical data of 141 patients with HCC complicated with obstructive jaundice were analyzed retrospectively. The patients underwent PTCD first. When the total bilirubin decreased, the patients received TACE or Apatinib treatment. They were divided into two groups: (1) PTCD+TACE group, N=68; (2) PTCD+Apatinib group, N=73.

Results: The PTCD+TACE group had higher ORR and DCR than the PTCD+Apatinib group (57.4% vs 12.3%, p < 0.001; 80.9% vs 60.3%, p = 0.010). The mPFS of the PTCD+TACE group was longer than that of the PTCD+Apatinib group (7.1 months vs 3.8 months, p < 0.001). The mOS of the PTCD+TACE group was longer than that of the PTCD+Apatinib group(11.5 months vs 7.7 months, p < 0.001). In the subgroup analysis of the PTCD+TACE group, the results showed that the survival benefits of the groups with total bilirubin <2 times and 2-3 times were greater.

Conclusion: In patients with HCC and obstructive jaundice, superselective TACE(lipiodol+epirubicin emulsion) significantly prolonged OS and PFS compared with Apatinib after using PTCD to reduce total bilirubin to <100 μmol/L. Patients whose total bilirubin dropped to .3 times of the upper limit of normal value after PTCD had longer OS and PFS than patients >3 times.

References

Chidambaranathan-Reghupaty S, Fisher P, Sarkar D . Hepatocellular carcinoma (HCC): Epidemiology, etiology and molecular classification. Adv Cancer Res. 2021; 149:1-61. PMC: 8796122. DOI: 10.1016/bs.acr.2020.10.001. View

Kulik L, El-Serag H . Epidemiology and Management of Hepatocellular Carcinoma. Gastroenterology. 2018; 156(2):477-491.e1. PMC: 6340716. DOI: 10.1053/j.gastro.2018.08.065. View

Yang J, Hainaut P, Gores G, Amadou A, Plymoth A, Roberts L . A global view of hepatocellular carcinoma: trends, risk, prevention and management. Nat Rev Gastroenterol Hepatol. 2019; 16(10):589-604. PMC: 6813818. DOI: 10.1038/s41575-019-0186-y. View

Dimitroulis D, Damaskos C, Valsami S, Davakis S, Garmpis N, Spartalis E . From diagnosis to treatment of hepatocellular carcinoma: An epidemic problem for both developed and developing world. World J Gastroenterol. 2017; 23(29):5282-5294. PMC: 5550777. DOI: 10.3748/wjg.v23.i29.5282. View

Woo H, Han S, Heo J, Kim D, Baek D, Yoo S . Role of endoscopic biliary drainage in advanced hepatocellular carcinoma with jaundice. PLoS One. 2017; 12(11):e0187469. PMC: 5667855. DOI: 10.1371/journal.pone.0187469. View

Minami Y, Kudo M . Hepatocellular carcinoma with obstructive jaundice: endoscopic and percutaneous biliary drainage. Dig Dis. 2012; 30(6):592-7. DOI: 10.1159/000343087. View

Qin L, Tang Z . Hepatocellular carcinoma with obstructive jaundice: diagnosis, treatment and prognosis. World J Gastroenterol. 2003; 9(3):385-91. PMC: 4621546. DOI: 10.3748/wjg.v9.i3.385. View

Suh Y, Kim D, Han K, Seong J . Effective biliary drainage and proper treatment improve outcomes of hepatocellular carcinoma with obstructive jaundice. Gut Liver. 2014; 8(5):526-35. PMC: 4164257. DOI: 10.5009/gnl13370. View

Park S, Park J, Chung M, Chung J, Park S, Han K . The efficacy of endoscopic palliation of obstructive jaundice in hepatocellular carcinoma. Yonsei Med J. 2014; 55(5):1267-72. PMC: 4108811. DOI: 10.3349/ymj.2014.55.5.1267. View

10.

Tanaka T, Kuzuya T, Ishigami M, Ito T, Ishizu Y, Honda T . Efficacy and Safety of Sorafenib in Unresectable Hepatocellular Carcinoma with Bile Duct Invasion. Oncology. 2020; 98(9):621-629. DOI: 10.1159/000507051. View

11.

Lai E, Lau W . Hepatocellular carcinoma presenting with obstructive jaundice. ANZ J Surg. 2006; 76(7):631-6. DOI: 10.1111/j.1445-2197.2006.03794.x. View

12.

. EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. J Hepatol. 2018; 69(1):182-236. DOI: 10.1016/j.jhep.2018.03.019. View

13.

Sugiyama G, Okabe Y, Ishida Y, Saitou F, Kawahara R, Ishikawa H . Evaluation of endoscopic biliary stenting for obstructive jaundice caused by hepatocellular carcinoma. World J Gastroenterol. 2014; 20(22):6968-73. PMC: 4051939. DOI: 10.3748/wjg.v20.i22.6968. View

14.

An J, Lee K, Kim K, Park D, Lee S, Lee D . Clinical features and outcomes of patients with hepatocellular carcinoma complicated with bile duct invasion. Clin Mol Hepatol. 2017; 23(2):160-169. PMC: 5497660. DOI: 10.3350/cmh.2016.0088. View

15.

Reig M, Forner A, Rimola J, Ferrer-Fabrega J, Burrel M, Garcia-Criado A . BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update. J Hepatol. 2021; 76(3):681-693. PMC: 8866082. DOI: 10.1016/j.jhep.2021.11.018. View

16.

Na S, Yim S, Suh S, Jung Y, Kim J, Seo Y . ALBI versus Child-Pugh grading systems for liver function in patients with hepatocellular carcinoma. J Surg Oncol. 2018; 117(5):912-921. DOI: 10.1002/jso.24992. View

17.

Han K, Kim J . Transarterial chemoembolization in hepatocellular carcinoma treatment: Barcelona clinic liver cancer staging system. World J Gastroenterol. 2015; 21(36):10327-35. PMC: 4579879. DOI: 10.3748/wjg.v21.i36.10327. View

18.

GOLDSTEIN H, Wallace S, Anderson J, Bree R, GIANTURCO C . Transcatheter occlusion of abdominal tumors. Radiology. 1976; 120(3):539-45. DOI: 10.1148/120.3.539. View

19.

Lencioni R, Petruzzi P, Crocetti L . Chemoembolization of hepatocellular carcinoma. Semin Intervent Radiol. 2014; 30(1):3-11. PMC: 3700789. DOI: 10.1055/s-0033-1333648. View

20.

Sieghart W, Hucke F, Peck-Radosavljevic M . Transarterial chemoembolization: modalities, indication, and patient selection. J Hepatol. 2015; 62(5):1187-95. DOI: 10.1016/j.jhep.2015.02.010. View